share_log

Goldman Sachs Maintains Neutral on BioXcel Therapeutics, Raises Price Target to $26

Benzinga Real-time News ·  Jan 26, 2023 08:25

Goldman Sachs analyst Corinne Jenkins maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and raises the price target from $16 to $26.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment